Welcome to our dedicated page for Joint SEC filings (Ticker: JYNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Joint Corp. filings document the regulatory record for a public chiropractic-care franchisor and clinic operator. Its 8-K reports cover operating and financial results, earnings presentations, material agreements, and capital-structure matters tied to credit facilities, covenants, restricted payments, and share repurchase capacity.
Proxy and governance filings describe director elections, board nomination matters, executive compensation, equity awards, shareholder voting items, and common-stock ownership disclosures. The company’s formal filings also record agreements related to corporate governance and the financing structure that supports its franchise-focused clinic network.
Pant Milind reported acquisition or exercise transactions in this Form 4 filing.
The Joint Corp director Pant Milind received a stock grant reported on Form 4. He was awarded 5,714 shares of Common Stock as a grant or award, rather than an open-market purchase or sale, and now directly holds 5,714 shares.
All of these shares are restricted and will vest in full on the earlier of May 20, 2027 or the date of the next annual meeting of The Joint Corp’s stockholders, making this a standard equity compensation award tied to future service.
JOINT Corp director Milind Pant filed an initial ownership report showing no current holdings of the company’s stock. The Form 3 indicates that, as of the reported date, no securities of JOINT Corp are beneficially owned, and total direct holdings are listed as zero shares.
Karrmann Sandra R reported acquisition or exercise transactions in this Form 4 filing.
JOINT Corp director Sandra R. Karrmann received a grant of 5,714 shares of restricted common stock, with no cash paid per share. These restricted shares vest in full on the earlier of May 20, 2027 or the next annual meeting of stockholders. Following this award, she directly holds 10,563 common shares.
Grandpre Christopher M reported acquisition or exercise transactions in this Form 4 filing.
JOINT Corp director Christopher M. Grandpre received an equity grant of 5,714 shares of Common Stock. The award was granted at no cash cost as restricted shares. All 5,714 shares vest in full on the earlier of May 20, 2027 or the next annual meeting of JOINT Corp stockholders. Following this grant, Grandpre directly holds a total of 45,097 Common Stock shares, reflecting a routine stock-based compensation award rather than an open-market purchase or sale.
Joint Corp director Ronald V. DaVella received an equity award of 5,714 shares of Common Stock. These shares are restricted and were granted at no purchase price. They will vest in full on the earlier of May 20, 2027 or the date of the next annual meeting of the stockholders of The Joint Corp.
After this grant, DaVella directly holds a total of 23,243 Joint Corp common shares. As a grant/award acquisition, this is a compensation-related transaction rather than an open-market trade.
JOINT Corp director Matthew E. Rubel received a grant of 5,714 shares of Common Stock as compensation. The shares were acquired at a stated price of $0.00 per share and increase his direct holdings to 23,177 shares following the transaction. All of the granted shares are restricted and will vest in full on the earlier of May 20, 2027 or the date of the next annual meeting of the stockholders of The Joint Corp.
The Joint Corp. reported results from its 2026 annual stockholder meeting held on May 20, 2026. Stockholders elected seven directors to serve until the 2027 annual meeting, with each nominee receiving over 9.8 million votes in favor and substantial support relative to votes against.
Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers and supported holding this advisory vote on executive pay every year. They also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, with more than 12.7 million votes in favor.
JOINT Corp ownership update: Charles E. Jobson filed an Amendment No. 4 to a Schedule 13G/A reporting beneficial ownership of 1,793,854 shares of Common Stock, representing 12.52% of the class. The filing states Mr. Jobson has sole voting and sole dispositive power over these shares. The filing is signed by Charles E. Jobson on 05/15/2026.
JOINT Corp major shareholder Charles E. Jobson increased his stake through open-market buying. He purchased a total of 148,051 shares of common stock on May 12–13 at a price of $8.57 per share. After these purchases, he directly owns 1,793,854 common shares of JOINT Corp, reflecting continued direct exposure as a more than ten percent owner.
The Joint Corp. reported first-quarter 2026 results with continuing-operations revenue of $14.8 million, up from $13.1 million a year earlier, and net income of $1.3 million versus $1.0 million.
Continuing operations swung to a $1.1 million profit from a prior-year loss as franchising and fee-based revenues grew while costs stayed controlled. The corporate clinic segment is classified as discontinued operations as the company pursues a major refranchising strategy; revenue from those clinics fell to $9.4 million from $16.9 million, reflecting progress on clinic sales. Cash and cash equivalents were $20.7 million, with total assets of $57.9 million and liabilities of $42.4 million. The company repurchased $1.1 million of stock under its buyback program and ended the quarter with 868 franchised clinics and 943 total clinics in operation.